Avloquin 50 mg/5 ml (Syrup)
Medicine Details
| Category | Details |
|---|---|
| Generic | Chloroquine phosphate |
| Company | Aci limited |
| Also available as |
Title
Avloquin
Categories
- Anti-malarial drugs
- Medication
Description
Avloquin is indicated for the treatment and prevention of malaria, as well as for the treatment of amoebic hepatitis and abscess, discoid and systemic lupus erythematosus, and rheumatoid arthritis. It is also used for the management of photoallergic reactions and porphyria cutanea tarda.
Dosage & Administration
- Tablet form: Each film coated tablet contains Chloroquine Phosphate BP 250 mg equiv. to approx. 150 mg of Chloroquine base
- Syrup form: Each 5 mL contains Chloroquine Phosphate BP 80 mg equiv. to approx. 50 mg of Chloroquine base
- Adult dosage: 25 mg of chloroquine base per kg body-weight given over 3 days
- Children dosage: A weekly oral dose of 5 mg per kg body-weight
Composition
- Chloroquine Phosphate BP 250 mg
- Chloroquine base 150 mg
- Chloroquine Phosphate BP 80 mg
- Chloroquine base 50 mg
Indications
- Treatment of malaria
- Prophylaxis and suppression of malaria
- Treatment of amoebic hepatitis and abscess
- Treatment of discoid and systemic lupus erythematosus
- Treatment of rheumatoid arthritis
Pharmacology
Chloroquine Phosphate is a 4-aminoquinoline antimalarial and amoebicidal agent used for the suppression and clinical cure of malaria due to susceptible strains of Plasmodium falciparum, P. ovale, P. vivax and P. malariae
Interaction
- Neostigmine
- Pyridostigmine
- Antacids
- Quinine
- Mefloquine
- Amodiaquine
- Artemisinin
- Metronidazole
- Ampicillin
Contraindications
- Known or suspected chloroquine resistance in P. falciparum
- Hypersensitivity
- Retinal damage
- Concurrent therapy with hepatotoxic drugs
Side Effects
- Gastro-intestinal: Nausea, vomiting and diarrhoea
- Psychological: Psychotic episodes, anxiety and personality changes
- Visual disturbances: Blurred vision and difficulties in focusing, keratopathy, retinopathy
- Haematological: Aplastic anaemia, agranulocytosis, thrombocytopenia and neutropenia
- Others: Loss of hair, photosensitivity, tinnitus
Pregnancy & Lactation
The use of chloroquine during pregnancy should be avoided except in the suppression or treatment of malaria when in the judgement of the physician the benefit outweighs the possible hazard. Nursing mothers should consider discontinuing the drug based on its importance to the mother.
Precautions & Warnings
- The eyes should be examined before starting long-term treatment and should be monitored subsequently
- Visual disturbances may render patients unfit to take charge of vehicles or machinery
- Care is necessary in administering to patients with impaired liver or renal function or to those with prophyria, psoriasis, or a history of epilepsy
- Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency should be observed for haemolytic anaemia during chloroquine treatment
Storage Conditions
Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.